Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Steurer

Showing results (61-70 of 78) with videos related to

Pageof 8
Sort By:
American Journal of Hematology|September 16, 2020
The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic eventMaurus Locher, Michael Steurer, Emina Jukic, et al.
Genes, Chromosomes & Cancer|December 5, 2020
Clonal dynamics in a composite chronic lymphocytic leukemia and hairy cell leukemia-variantMaurus Locher, Emina Jukic, Jan-Paul Bohn, et al.
Annals of Hematology|June 24, 2018
Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II studyAlexander Egle, Michael Steurer, Thomas Melchardt, et al.
Annals of Hematology|June 5, 2018
Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II studyAlexander Egle, Michael Steurer, Thomas Melchardt, et al.
Wiener Klinische Wochenschrift|September 17, 2015
Iron metabolism and iron supplementation in cancer patientsHeinz Ludwig, Rayko Evstatiev, Gabriela Kornek, et al.
Haematologica|May 18, 2019
Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemiaMichael Steurer, Marco Montillo, Lydia Scarfò, et al.
Leukemia & Lymphoma|January 20, 2016
Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemiaAnders Österborg, Miklós Udvardy, Andrey Zaritskey, et al.
American Journal of Hematology|December 23, 2011
Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignanciesAna Puda, Jelena D Milosevic, Tiina Berg, et al.
Wiener Klinische Wochenschrift|March 3, 2012
[Primary immune thrombocytopenia in adults: diagnostics and treatment consensus statement of the Austrian Society of Hematology and Oncology (ÖGHO)]Ingrid Pabinger, Günther Gastl, Michael Steurer, et al.
Journal of the National Cancer Institute|February 5, 2014
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patientsCarlo Gambacorti Passerini, Francesca Farina, Alessandra Stasia, et al.
Pageof 8

Showing results (61-70 of 78) with videos related to

Sort By:
Pageof 8
American Journal of Hematology|September 16, 2020
The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic eventMaurus Locher, Michael Steurer, Emina Jukic, et al.
Genes, Chromosomes & Cancer|December 5, 2020
Clonal dynamics in a composite chronic lymphocytic leukemia and hairy cell leukemia-variantMaurus Locher, Emina Jukic, Jan-Paul Bohn, et al.
Annals of Hematology|June 24, 2018
Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II studyAlexander Egle, Michael Steurer, Thomas Melchardt, et al.
Annals of Hematology|June 5, 2018
Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II studyAlexander Egle, Michael Steurer, Thomas Melchardt, et al.
Wiener Klinische Wochenschrift|September 17, 2015
Iron metabolism and iron supplementation in cancer patientsHeinz Ludwig, Rayko Evstatiev, Gabriela Kornek, et al.
Haematologica|May 18, 2019
Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemiaMichael Steurer, Marco Montillo, Lydia Scarfò, et al.
Leukemia & Lymphoma|January 20, 2016
Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemiaAnders Österborg, Miklós Udvardy, Andrey Zaritskey, et al.
American Journal of Hematology|December 23, 2011
Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignanciesAna Puda, Jelena D Milosevic, Tiina Berg, et al.
Wiener Klinische Wochenschrift|March 3, 2012
[Primary immune thrombocytopenia in adults: diagnostics and treatment consensus statement of the Austrian Society of Hematology and Oncology (ÖGHO)]Ingrid Pabinger, Günther Gastl, Michael Steurer, et al.
Journal of the National Cancer Institute|February 5, 2014
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patientsCarlo Gambacorti Passerini, Francesca Farina, Alessandra Stasia, et al.
Pageof 8